company background image
CVSI logo

CV Sciences OTCPK:CVSI Stock Report

Last Price

US$0.041

Market Cap

US$7.5m

7D

9.1%

1Y

9.0%

Updated

30 Jan, 2025

Data

Company Financials

CVSI Stock Overview

Develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. More details

CVSI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CV Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CV Sciences
Historical stock prices
Current Share PriceUS$0.041
52 Week HighUS$0.10
52 Week LowUS$0.028
Beta0.66
1 Month Change19.91%
3 Month Change-15.56%
1 Year Change8.95%
3 Year Change-71.15%
5 Year Change-95.57%
Change since IPO-92.35%

Recent News & Updates

Recent updates

Shareholder Returns

CVSIUS Personal ProductsUS Market
7D9.1%1.0%-0.8%
1Y9.0%-22.1%25.2%

Return vs Industry: CVSI exceeded the US Personal Products industry which returned -22.1% over the past year.

Return vs Market: CVSI underperformed the US Market which returned 25.2% over the past year.

Price Volatility

Is CVSI's price volatile compared to industry and market?
CVSI volatility
CVSI Average Weekly Movement12.5%
Personal Products Industry Average Movement8.4%
Market Average Movement6.5%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: CVSI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CVSI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201043Joe Dowlingwww.cvsciences.com

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. The company offers its products under the PlusCBD, ProCBD, HappyLane, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.

CV Sciences, Inc. Fundamentals Summary

How do CV Sciences's earnings and revenue compare to its market cap?
CVSI fundamental statistics
Market capUS$7.52m
Earnings (TTM)-US$2.54m
Revenue (TTM)US$15.62m

0.5x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CVSI income statement (TTM)
RevenueUS$15.62m
Cost of RevenueUS$8.39m
Gross ProfitUS$7.23m
Other ExpensesUS$9.77m
Earnings-US$2.54m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin46.30%
Net Profit Margin-16.24%
Debt/Equity Ratio33.9%

How did CVSI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 23:09
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CV Sciences, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pablo ZuanicCantor Fitzgerald & Co.
Michael GrondahlNorthland Capital Markets
Michael LaveryPiper Sandler Companies